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At the dawn of interventional cardiology, Andreas Grüntzig
remarked that balloon angioplasty was limited by anatomic
factors such as ﬁbrotic or calciﬁed stenoses (1). Subse-
quently, in large series of patients undergoing balloon an-
gioplasty, coronary calciﬁcation was one of the factors
associated with a lack of initial success (2). Techniques such
as higher inﬂation pressures and rotational atherectomy were
developed in part to deal with heavily calciﬁed lesions.
With the advent of coronary stents, it was rapidly appreci-
ated that heavy calciﬁcation could interfere with full stent
expansion (3). In the long-term follow-up of patients with
drug-eluting stents, moderate-to-severe target lesion calci-
ﬁcation (TLC) was one of the independent predictors of
stent thrombosis (4).See page 1845In this issue of the Journal, Généreux et al. (5) reported
on the frequency and clinical impact of coronary calciﬁ-
cation among patients with acute coronary syndrome
(ACS) undergoing percutaneous coronary intervention
(PCI) in 2 large clinical trials. Severe or moderate TLC
was present in 5.9% and 26.1% of 6,855 patients, respec-
tively, and was associated in univariate analysis with
signiﬁcantly higher rates of death, cardiac death, stent
thrombosis, and ischemic target lesion and target vessel
revascularization at 1 year compared with patients with
mild or no TLC. These ﬁndings may not be surprising but
are important because the frequency and effect of TLC in
patients with ACS undergoing PCI have not previously
been reported in a large cohort with structured follow-up
and with TLC assessed uniformly by a core laboratory.
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view held that coronary calciﬁcation is more likely to be
associated with stable as compared with unstable coronary
lesions (6) and that lipid pools, but not calcium, increase
stress and instability of coronary plaques (7). More recent
evidence indicates that microcalciﬁcations within the ﬁbrous
cap increase stress and plaque instability (8,9). Such
microcalciﬁcations are too small to be viewed by the usual
techniques; however, by intravascular ultrasound (IVUS),
most rupture-prone plaques show speckled or diffuse calci-
ﬁcation (10).
In this context, the high rates of TLC in this study were
unexpected: 27% of patients with non–ST-segment eleva-
tion ACS and 38% of patients with ST-segment elevation
myocardial infarction (STEMI) had 1 or more moderately
or severely calciﬁed target lesions treated with PCI. This
degree of calciﬁcation, because it is grossly visible by ﬂuo-
roscopy, is much more severe than the diffuse speckled
calciﬁcations seen with IVUS (10) or the microcalciﬁcation
seen in tissue samples with high-resolution imaging (9). A
partial explanation for the high prevalence of TLC in this
study is that the lesions treated with PCI might not always
correspond to the culprit lesion responsible for the ACS
event; indeed, the number of treated lesions per patient
ranged from 1.31 to 1.40, depending on the category of
calciﬁcation. Nevertheless, the traditional concept, that
plaque rupture occurs in lipid-laden lesions without calcium
and that calciﬁed lesions are relatively safe, appears to be an
oversimpliﬁcation.
Afﬁxing blame: the patient, the lesion, or the stent?
Patients with moderate or severe TLC in this study were
older, had more renal insufﬁciency, had lower ejection frac-
tions, and were more likely to have had a STEMI compared
with patients with no or mild TLC. Thus, if moderate
or severe TLC by itself had no effect on the immediate
and long-term effects of PCI, these patients would still be
likely to have a worse outcome due to these adverse clinical
features.
On the other hand, lesions with moderate or severe TLC
also have other characteristics that are unfavorable, including
longer lesion length, more total occlusions, more visible
thrombi, and more triple-vessel disease. If patients with
more TLC had clinical features similar to patients with no or
mild TLC, their post-PCI prognosis would still be worse
because of their unfavorable lesion features. After the pro-
cedure, Thrombolysis In Myocardial Infarction (TIMI) ﬂow
grade 3 had been attained in 93.1% of patients with no or
mild TLC, 91.6% of those with moderate TLC, and only
85.9% of those with severe TLC (p < 0.0001). This alone
presages a worse prognosis for the latter group.
But what about the stent itself? Calciﬁcation may prevent
complete expansion of the stent or interfere with stent
delivery, resulting in damage either to the structure of the
stent or to the polymer in the case of drug-eluting stents.
A malapposed, incompletely expanded, or damaged stent
increases the risks for stent thrombosis and target lesion
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1856revascularization. In this study, these were the 2 endpoints
that TLC predicted by multivariate analysis.
Compared with ﬂuoroscopy, IVUS provides far more
information about TLC. In one series of 110 patients un-
dergoing PCI, ﬂuoroscopy detected TLC in approximately
one-half of the patients, whereas IVUS detected TLC in
about three-quarters (11). TLC was categorized by IVUS
according to the number of quadrants involved, superﬁcial
or deep involvement, and axial length of calciﬁcation. Such
information should be helpful in planning the type of
intervention.
Coronary calciﬁcation is also an adverse prognostic factor
in patients undergoing coronary bypass surgery. In a com-
panion study to this one (12), with the same core laboratory
to categorize coronary calciﬁcation, severe calciﬁcation was
present in 13.6% of patients before bypass surgery and was
an independent predictor of major adverse cardiac events at
1 year (hazard ratio: 1.77; 95% conﬁdence interval: 1.18 to
2.66; p ¼ 0.006).
Coronary calciﬁcation is associated with aortic valve
calciﬁcation, mitral annular calciﬁcation, and calciﬁcation of
the thoracic aorta (13). Calciﬁcation of the thoracic aorta has
been shown to be a strong predictor of cardiovascular events
and death in patients with stable angina (13).
Practical implications. As the authors point out, inter-
ventional cardiologists tend to underestimate the degree of
TLC. Would recognition of TLC improve outcomes? IVUS
guidance to conﬁrm optimal stent expansion and apposition
and to check for hidden dissection might improve outcomes
(14) and would be most appropriate for heavily calciﬁed
lesions. TLC correlates with increased platelet reactivity
despite aspirin and clopidogrel use (15). The use of more
potent antiplatelet drugs such as prasugrel or ticagrelor
instead of clopidogrel might be warranted for heavily calci-
ﬁed lesions, although this has not been proven.
In conclusion, Généreux et al. have done us a service by
highlighting the continuing bad consequences of TLC.
Despite huge advances in PCI technology over nearly 50
years, the curse of calciﬁcation persists.
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